Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments

Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments

Biliary tract cancers (BTCs) are rare tumours, most often diagnosed at an unresectable stage, associated with poor prognosis, with a 5-year survival rate not exceeding 10%. Only first- and second-line treatments are well codified with the combination of cisplatin-gemcitabine chemotherapy and immunot...

Full description

Bibliographic Details
Main Authors: Marine Valery, Damien Vasseur, Francesco Fachinetti, Alice Boilève, Cristina Smolenschi, Anthony Tarabay, Leony Antoun, Audrey Perret, Alina Fuerea, Thomas Pudlarz, Valérie Boige, Antoine Hollebecque, Michel Ducreux
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Cancers
Subjects:
biliary tract cancers
molecular targetable alterations
targeted therapies
<i>FGFR2</i> fusion
<i>IDH1</i> mutation
Online Access:https://www.mdpi.com/2072-6694/15/18/4446

Internet

https://www.mdpi.com/2072-6694/15/18/4446

Similar Items